Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest aplastic anemia Stories

2010-12-02 12:46:00

Give Blood Now and Help a Neighbor This Season NEW YORK, Dec. 2, 2010 /PRNewswire-USNewswire/ -- December is Aplastic Anemia Awareness Month, and New York Blood Center (NYBC) serving more than 20 million people in New York City, Long Island, the Hudson Valley, New Jersey, and parts of Connecticut and Pennsylvania, calls upon the community to please take a few minutes from the holiday shuffle to donate blood, the gift of life, and help replenish and boost your community supply this season....

2010-10-04 13:48:00

- Dr. Monica Bessler Launches New Center to Study, Treat Bone Marrow Failure - PHILADELPHIA, Oct. 4 /PRNewswire-USNewswire/ -- One of the world's leading experts in bone marrow failure and related blood disorders recently joined The Children's Hospital of Philadelphia. Hematology researcher Monica Bessler, M.D., Ph.D., arrived at the hospital this summer to establish a new program, the Pediatric and Adult Comprehensive Bone Marrow Failure Center. Dr. Bessler becomes the first person to...

2010-09-24 08:52:57

(Ivanhoe Newswire) -- Among patients receiving immunosuppressive therapy for severe aplastic anemia, a condition in which the bone marrow is unable to produce blood cells, the length of telomeres (chromosome markers of biological aging) was clearly associated with a higher rate of relapse and lower overall survival. Severe aplastic anemia is characterized by life-threateningly low blood cell counts, but the condition can be treated by bone marrow transplant or immunosuppressive drugs. In...

2010-08-18 18:33:38

Although hematopoietic cell transplantation (HCT) cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure, according to a recent study published online in Blood, the journal of the American Society of Hematology. Overall, these patients were three and a half times more likely to develop a severe or life-threatening health condition, such as cardiovascular, endocrine, or musculoskeletal problems, as well as new cancers, when...

2010-03-11 08:54:52

DALLAS -- Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions. Reducing platelet transfusions, and lowering the threshold on when to administer transfusions could help address frequent shortages in platelet supplies, said Dr. Victor Aquino, associate professor of pediatrics and an author...

2008-12-09 06:00:00

CHESHIRE, Conn., Dec. 9 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), was observed by investigators to reduce blood measures associated with undiagnosed blood clots and inflammation in patients with PNH. A separate study found that Soliris was observed to reduce indicators of pulmonary artery hypertension (PAH) in patients with paroxysmal nocturnal hemoglobinuria (PNH), according to a new...

2008-12-08 12:30:00

CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported positive results from AEGIS, an open-label registration study examining Soliris(R) (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified primary efficacy endpoint of change in hemolysis was achieved with an 86 percent reduction (P<0.001). Key secondary endpoints including fatigue (P<0.001) and transfusions/anemia...

2008-12-04 09:29:00

People with Rare Anemias, Blood Cancers Need You NEW YORK, Dec. 4 /PRNewswire-USNewswire/ -- As winter holidays fast approach, New York Blood Center (NYBC) calls upon the community to please set aside a time to donate blood. The holidays are a time when blood supply decreases while emergency needs remain the same. It is also a time when it becomes more difficult to find precise blood matches for those that are very sick. December is also Aplastic Anemia Awareness Month. Aplastic anemia...

2008-12-02 08:00:00

Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire/ -- Eisai Corporation of North America today announced that it plans to initiate the first clinical trial evaluating the activity of Dacogen(R) (decitabine for injection) compared to Vidaza(R) (azacitidine) in adult patients with intermediate-1, intermediate-2 or high-risk myelodysplastic syndromes (MDS), a potentially life-threatening group of bone...

2008-10-30 09:00:11

The Aplastic Anemia & MDS International has announced that the European Committee for Medicinal Products for Human Use has awarded Vidaza a positive opinion for the treatment of myelodysplastic syndromes patients who are not eligible for stem cell transplants. The Committee for Medicinal Products for Human Use's (CHMP's) positive opinion is based on data from the AZA-001 trial, which has demonstrated an overall survival benefit for higher-risk myelodysplastic syndromes (MDS) patients....